Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure

Phase 2

Terminated

Conditions: Solid Tumors Induced by Prior Radiation Exposure

Interventions: Drug: Nivolumab

Registration Number: NCT02864316

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary: The purpose of this study is to determine whether Nivolumab is effective in the treatment of radiation-induced solid tumors.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 6

Inclusion Criteria

Histologically confirmed metastatic or unresectable solid tumor which standard curative or palliative measures do not exist or are no longer effective. The primary site of the metastatic or unresectable tumor must have arisen within a previously irradiated site and be considered a radiation-induced tumor.
Pre-treatment tumor specimen available. Patients with no available archived specimen must be willing to undergo a pre-treatment tumor biopsy.
Measurable disease.
Progressive disease on study entry.
Received adjuvant or neoadjuvant chemotherapy and developed recurrent or metastatic disease within 6 months of completing therapy.
Age >18 years.
Eastern Cooperative Oncology Group (ECOG) performance status <2.
Life expectancy of greater than 3 months.
Adequate organ and marrow function as defined below:
White Blood Cell >2,000/per microliter
Absolute neutrophil count >1,500/per microliter
Platelets >100,000/per microliter
Hemoglobin ≥9.0 g/dL
Total bilirubin ≤1.5 times the institutional upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
Aspartate Aminotransferase(SGOT)/Alanine Aminotransferase (SGPT) <3 X institutional ULN
Creatinine ≤1.5 X institutional ULN OR
Creatinine clearance >40 mL/min for patients with creatinine Levels above institutional normal (calculated using the Cockcroft-Gault formula below)
Female Creatinine Clearance = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL
Male Creatinine Clearance = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
Women of childbearing potential (WOCBP) and men must agree to use adequate contraception prior to study entry and for the duration of study participation and up to 31 weeks after the last dose of nivolumab.
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of nivolumab.
Ability to understand and the willingness to sign a written informed consent document.
Biopsiable disease at the time of enrollment as biopsies after progression are required for participation.

Exclusion Criteria

Any active, known or suspected autoimmune disease.
Requiring continuous supplemental oxygen.
Chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or unresolved toxicity due to agents administered more than 2 weeks earlier.
Uncontrolled brain metastases.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.
Uncontrolled inter-current illness.
Pregnant or currently breastfeeding.
Receiving any other anticancer therapy.
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA- 4 antibody therapies, any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
History of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating ongoing acute or chronic infection.
Requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study drug administration.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Radiation-Induced Non-Sarcoma Metastatic Solid Tumors	Nivolumab	a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
Radiation-Induced Metastatic Sarcoma	Nivolumab	a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.

Primary Outcome Measures

Name	Time	Method
Best Objective Response Rate	Up to 24 weeks	Number of participants with response. Response will be assessed at baseline (within 4 weeks prior to starting nivolumab) and then every 8 weeks while on Nivolumab, up to 24 weeks. The best objective response will be assessed at 24 weeks. Response will be defined based on RECIST 1.1 criteria where complete response (CR)= disappearance of all target lesions, partial response (PR) is =\>30% decrease in sum of diameters of target lesions, progressive disease (PD) is \>20% increase in sum of diameters of target lesions, stable disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Treatment-related Adverse Events	up to 100 days post-intervention	Number of participants with treatment-related adverse events as defined by CTCAE 4.0 criteria.
Overall Survival	Up to 22 months	Overall survival was planned to be measured at 5 years post-intervention as the time from enrollment until death. Instead, due to early termination for low accrual, the number of participants alive at the time of study termination is reported.
Percentage of Patients Progression-free at 24 Weeks From the Time of Enrollment	24 weeks	Disease status at 24 weeks will be compared to disease status at the time of enrollment, and response coded based on RECIST 1.1 criteria.
Progression-free Survival	Up to 22 months	Number of participants alive without progression.
Duration of Response	Up to 22 months	The duration of overall response is measured from the time measurement criteria are met for Complete Response or Partial Response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, accessed up to 3 years.